Patent application number | Description | Published |
20080214536 | Amido-Substituted 6-Phenylphenanthridines - Compounds of a certain formula (I) | 09-04-2008 |
20090030065 | Use of Pde1c and Inhibitors Thereof - The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases. | 01-29-2009 |
20090215836 | Roflumilast for the Treatment of Pulmonary Hypertension - The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension. | 08-27-2009 |
20090239895 | Novel 3-thia-10-aza-phenanthrene derivatives - The compounds of formula I | 09-24-2009 |
20100120757 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compounds of a certain formula 1, | 05-13-2010 |
20100234382 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR - The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental. | 09-16-2010 |
20110218201 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS - The compounds of Formula (I), | 09-08-2011 |
20120196867 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR - The claimed subject matter relates to pharmaceutical compositions comprising a PDE4 inhibitor and a PDE5 inhibitor and the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental. | 08-02-2012 |
20120289474 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES - The compounds of Formula (1), | 11-15-2012 |
20130012544 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase. | 01-10-2013 |
20140073672 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS - The compounds of Formula (I), | 03-13-2014 |
20140112945 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES - The compounds of formula (1) | 04-24-2014 |
20140113877 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C] ISOQUINOLINE COMPOUNDS - The compounds of formula (1) | 04-24-2014 |
20140378509 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis. | 12-25-2014 |